PT - JOURNAL ARTICLE AU - Dalrymple, Ashley N AU - Fisher, Lee E AU - Weber, Douglas J TI - Transcutaneous Spinal Cord Stimulation to Reduce Phantom Limb Pain in People with a Transtibial Amputation AID - 10.1101/2023.04.13.23288483 DP - 2023 Jan 01 TA - medRxiv PG - 2023.04.13.23288483 4099 - http://medrxiv.org/content/early/2023/04/17/2023.04.13.23288483.short 4100 - http://medrxiv.org/content/early/2023/04/17/2023.04.13.23288483.full AB - Phantom limb pain (PLP) is debilitating and affects over 70% of people with a lower-limb amputation. In chronic pain conditions, there are plastic changes at the spinal cord level, typically causing increased excitability. Altered spinal excitability can be measured using reflexes, such as the posterior root-muscle (PRM) reflex. Neuromodulation of the spinal cord can be used to reduce chronic pain in a variety of conditions. Here we propose using a non-invasive neuromodulation method, transcutaneous spinal cord stimulation (tSCS), to reduce PLP in people with transtibial amputation. We recruited three participants, two males (5- and 9-years post-amputation; alcohol- induced neuropathy, traumatic) and one female (3 months post-amputation; diabetic dysvascular) for this 5-day study. We measured their pain using pain questionnaires and the pain pressure threshold test. We measured spinal reflex excitability using PRM reflexes. We provided neuromodulation using tSCS at 30 Hz with a carrier frequency of 10 kHz for 30 minutes/day for 5 days. Mean pain scores decreased from 34.0±7.0 on Day 1 to 18.3±6.8 on Day 5, which was a clinically meaningful difference. Two participants had increased pain pressure thresholds across the residual limb (Day 1: 5.4±1.6 lbf; Day 5: 11.4±1.0 lbf). PRM reflexes had high thresholds (59.5±6.1 µC) and low amplitudes, suggesting that in PLP, reflexes are hypoexcitable. After 5 days of tSCS, reflex thresholds decreased significantly (38.6±12.2 µC; p<0.001). Overall, tSCS is a non- invasive neuromodulation method that can reduce PLP and modulate spinal reflexes.Competing Interest StatementDJW is a co-founder and shareholder of Reach Neuro, Inc.; DJW is a consultant and shareholder of Neuronoff, Inc.; DJW is a shareholder and scientific board member for NeuroOne Medical, Inc.; DJW is a shareholder of Bionic Power Inc., Iota Biosciences Inc., and Blackfynn Inc. The other authors declare no conflicts of interests in relation to this work.Clinical TrialNCT04543786Funding StatementResearch reported in this publication was supported by pilot funding from the National Institutes of Health National Center of Neuromodulation for Rehabilitation, the National Center for Complementary and Integrative Health, the National Institute on Deafness and Other Communication Disorders, and the National Institute of Neurological Disorders and Stroke. NIH/NICHD Grant Number P2CHD086844 which was awarded to the Medical University of South Carolina. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NICHD. This study was also funded by the Department of Mechanical Engineering and the Neuroscience Institute at Carnegie Mellon University. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Internal Review Board of Carnegie Mellon University gave ethical approval of this work (STUDY2021_00000343).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.